StemCell Therapy

Regulated information August 8, 2012

TiGenix completes patient enrollment in Phase IIa rheumatoid arthritis study

Leuven (BELGIUM), Madrid (SPAIN) - August 8, 2012 - TiGenix (NYSE Euronext: TIG), the European leader in cell therapy, announced today the completion of patient enrollment in the Company`s Phase IIa study of Cx611, a suspension of expanded allogeneic adult stem cells, in rheumatoid arthritis. The Phase IIa clinical trial is a 53-subject, multicenter, placebo-controlled study in 3 cohorts with different dosing regimens, designed to assess safety, feasibility, tolerance, and optimal dosing. The study is being conducted at 23 centers. The Company believes that this clinical trial can set the stage not only for the further development of Cx611 in RA, but also in a wide range of other autoimmune disorders.

"In addition to the primary endpoints of safety and optimal dosing, we expect this trial to yield a first indication of the duration of the efficacy of Cx611 in this very difficult patient population: the enrolled patients have previously failed to respond to at least two biologicals," said Eduardo Bravo, CEO of TiGenix. "In the trial patients are treated with three injections of Cx611. The six-month follow-up without further dosing should provide us with a truly meaningful result. This is the most advanced stem cell therapy trial in RA in the world, and completing the enrollment on time confirms our leadership position in the field. We anticipate reporting the results of the study no later than April 2013."

About Cx611 for rheumatoid arthritis Cx611 is a suspension of expanded allogeneic adult stem cells derived from human adipose (fat) tissue (expanded Adipose derived Stem Cells or `eASCs`) that is delivered through intra-venous injection for the treatment of rheumatoid arthritis. The objective of the Phase IIa trial is to determine safety, feasibility, tolerance, and optimal dosing. This multicentre, placebo-controlled study has enrolled 53 patients, divided in 3 cohorts with different dosing regimens. There are 23 centers open and the company expects the final results to be available in the first half of 2013.

For more information: Eduardo Bravo Chief Executive Officer eduardo.bravo@tigenix.com

Claudia D`Augusta Chief Financial Officer claudia.daugusta@tigenix.com Hans Herklots Director Investor & Media Relations hans.herklots@tigenix.com +32 16 39 60 97

About TiGenix

TiGenix NV (NYSE Euronext Brussels: TIG)is a leading European cell therapy companywith a marketed product for cartilage repair, ChondroCelect, and a strongpipeline with clinical stage allogeneic adult stem cell programsfor the treatment ofautoimmune and inflammatory diseases.TiGenixis based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (theNetherlands). For more information please visitwww.tigenix.com.

Forward-looking information

Go here to read the rest:
TiGenix : completes patient enrollment in Phase IIa rheumatoid arthritis study

This entry was posted on August 8, 2012 at 11:17 am and is filed under Arthritis. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |